Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions

American Journal of Pathology

Volumn 165, Issue 6, 2004, Pages 1853-1863

  Gerlini, Gianni ^b   Tun Kyi, Adrian ^a   Dudli, Christa ^a   Burg, Günter ^a   Pimpinelli, Nicola ^b   Nestle, Frank O ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY;

ANTIGEN RECOGNITION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TUMOR CELL;

EID: 9644260767     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63238-5     Document Type: Article

References (70)

1. Knowles RW, Bodmer WF: A monoclonal antibody recognizing a human thymus leukemia-like antigen associated with beta 2-microglobulin. Eur J Immunol 1982, 12:676-681
2. Terhorst C, van Agthoven A, LeClair K, Snow P, Reinherz E, Schlossman S: Biochemical studies of the human thymocyte cell-surface antigens T6, T9, and T10. Cell 1981, 23:771-780
3. Grant EP, Degano M, Rosat JP, Stenger S, Modlin RL, Wilson IA, Porcelli SA, Brenner MB: Molecular recognition of lipid antigens by T cell receptors. J Exp Med 1999, 189:195-205
4. Porcelli SA, Segelke BW, Sugita M, Wilson IA, Brenner MB: The CD1 family of lipid antigen-presenting molecules. Immunol Today 1998, 19:362-368
5. Blumberg RS, Gerdes D, Chott A, Porcelli SA, Balk SP: Structure and function of the CD1 family of MHC-like cell surface proteins. Immunol Rev 1995, 147:5-29
6. Balk SP, Bleicher PA, Terhorst C: Isolation and characterization of a cDNA and gene coding for a fourth CD1 molecule. Proc Natl Acad Sci USA 1989, 86:252-256
7. Rosat JP, Grant EP, Beckman EM, Dascher CC, Sieling PA, Frederique D, Modlin RL, Porcelli SA, Furlong ST, Brenner MB: CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ alpha beta T cell pool. J Immunol 1999, 162:366-371
8. Dutronc Y, Porcelli SA: The CD1 family and T cell recognition of lipid antigens. Tissue Antigens 2002, 60:337-353
9. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252
10. Porcelli SA, Modlin RL: The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 1999, 17:297-329
11. Cella M, Sallusto F, Lanzavecchia A: Origin, maturation, and antigen-presenting function of dendritic cells. Curr Opin Immunol 1997, 9:10-16
12. Fortsch D, Rollinghoff M, Stenger S: IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis. J Immunol 2000, 165:978-987
13. Stenger S, Modlin RL: T cell-mediated immunity to Mycobacterium tuberculosis. Curr Opin Microbiol 1999, 2:89-93
14. Sieling PA, Jullien D, Dahlem M, Tedder TF, Rea TH, Modlin RL, Porcelli SA: CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. J Immunol 1999, 162:1851-1858
15. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999, 163:2387-2391
16. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y, Taniguchi M: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998, 95:5690-5693
17. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF: IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 1999, 112:205-209
18. Livingston P: Ganglioside vaccines with emphasis on GM2. Semin Oncol 1998, 25:636-645
19. Livingston PO, Ragupathi G: Carbohydrate vaccines that induce antibodies against cancer: 2. Previous experience and future plans. Cancer Immunol Immunother 1997, 45:10-19
20. Carr A, Rodriguez E, Arango Mdel C, Camacho R, Osorio M, Gabri M, Carrillo G, Valdes Z, Bebelagua Y, Perez R, Fernandez LE: Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol 2003, 21:1015-1021
21. Fredman P, Hedberg K, Brezicka T: Gangliosides as therapeutic targets for cancer. BioDrugs 2003, 17:155-167
22. Irie RF, Matsuki T, Morton DL: Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1989, 1:786-787
23. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL: Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1985, 35:607-612
24. Kirkwood JM, Mascari RA, Edington HD, Rabkin MS, Day RS, Whiteside TL, Vlock DR, Shipe-Spotloe JM: Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 2000, 88:2693-2702
25. Dummer W, Bastian BC, Ernst N, Schanzle C, Schwaaf A, Brocker EB: Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996, 66:607-610
26. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D: Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001, 19:239-247
27. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G: Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II, and ICAM-1 molecules. Int J Cancer 1997, 71:630-637
28. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997, 27:3135-3142
29. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-332
30. Nestle FO, Burg G, Fah J, Wrone-Smith T, Nickoloff BJ: Human sunlight-induced basal cell carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 1997, 150:641-651
31. Kiertscher SM, Luo J, Dubinett SM, Roth MD: Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000, 164:1269-1276
32. Gerlini G, Hefti HP, Kleinhans M, Nickoloff BJ, Burg G, Nestle FO: Cd1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells. J Invest Dermatol 2001, 117:576-582
33. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB: Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995, 5:67-68
34. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI: Clinical significance of defective dendritic ceil differentiation in cancer. Clin Cancer Res 2000, 6:1755-1766
35. Thomssen H, Kahan M, Londei M: Differential effects of interleukin-10 on the expression of HLA class II and CD1 molecules induced by granulocyte/ macrophage colony-stimulating factor/interleukin-4. Eur J Immunol 1995, 25:2465-2470
36. Buelens C, Willems F, Delvaux A, Pierard G, Delvilie JP, Velu T, Goldman M: Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995, 25:2668-2672
37. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, Ho PJ, Hart D, Joshua D: Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001, 98:2992-2998
38. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G: Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001, 166:4312-4318
39. Sandhoff K, van Echten G: Ganglioside metabolism: enzymology, topology, and regulation. Prog Brain Res 1994, 101:17-29
40. Portoukalian J, Zwingelstein G, Dore JF: Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979, 94:19-23
41. Tsuchida T, Saxton RE, Morton DL, Irie RF: Gangliosides of human melanoma. J Natl Cancer Inst 1987, 78:45-54
42. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale Jr EM: Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001, 61:363-369
43. Grayson G, Ladisch S: Immunosuppression by human gangliosides: II. Carbohydrate structure and inhibition of human NK activity Cell Immunol 1992, 139:18-29
44. Birkle S, Zeng G, Gao L, Yu RK, Aubry J: Role of tumor-associated gangliosides in cancer progression. Biochimie 2003, 85:455-463
45. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB: Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature 1994, 372:691-694
46. Porcelli S, Morita CT, Brenner MB: CD1b restricts the response of human CD4-8-T lymphocytes to a microbial antigen. Nature 1992, 360:593-597
47. Stenger S, Mazzaccaro RJ, Uyemura K, Cho S, Barnes PF, Rosat JP, Sette A, Brenner MB, Porcelli SA, Bloom BR, Modlin RL: Differential effects of cytolytic T cell subsets on intracellular infection. Science 1997, 276:1684-1687
48. Prete SP, Giuliani A, Iona E, Fattorini L, Orefici G, Franzese O, Bonmassar E, Graziani G: Bacillus Calmette-Guerin down-regulates CD1b induction by granulocyte-macrophage colony stimulating factor in human peripheral blood monocytes. J Chemother 2001, 13:52-58
49. Houghton AN, Taormina MC, Ikeda H, Watanabe T, Oettgen HF, Old LJ: Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci USA 1980, 77:4260-4264
50. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987, 84:2911-2915
51. Portoukalian J, Carrel S, Dore JF, Rumke P: Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides: EORTC Cooperative Melanoma Group. Int J Cancer 1991, 49:893-899
52. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, et al.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994, 12:1036-1044
53. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001, 166:678-689
54. Chen Q, Daniel V, Maher DW, Hersey P: Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994, 56:755-760
55. Westphal JR, Van't Hullenaar R, Peek R, Willems RW, Crickard K, Crickard U, Askaa J, Clemmensen I, Ruiter DJ, De Waal RM: Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF, and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 2000, 86:768-776
56. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE: Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 1998, 77:1492-1494
57. Enk AH, Jonuleit H, Saloga J, Knop J: Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997, 73:309-316
58. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N, Schuler G: High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and down-regulation by IL-4 and IL-10. J Exp Med 1996, 184:741-746
59. Chang CH, Furue M, Tamaki K: B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol 1995, 25:394-398
60. Enk AH, Angeloni VL, Udey MC, Katz SI: Inhibition of Langerhans cell antigen-presenting function by IL-10: a role for IL-10 in induction of tolerance. J Immunol 1993, 151:2390-2398
61. Caux C, Massacrier C, Vanbervliet B, Barthelemy C, Liu YJ, Banchereau J: Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int Immunol 1994, 6:1177-1185
62. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH: Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999, 93:1634-1642
63. Fernandez Pujol B, Lucibello FC, Zuzarte M, Lutjens P, Muller R, Havemann K: Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol 2001, 80:99-110
64. Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y: Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 2004, 53:543-550
65. Fiedler T, Walter W, Reichert TE, Maeurer MJ: Regulation of CD1d expression by murine tumor cells: escape from immunosurveillance or alternate target molecules? Int J Cancer 2002, 98:389-397
66. Bhattacharyya S, Sen P, Wallet M, Long B, Baldwin AS, Tisch R: Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and I{kappa}B kinase activity. Blood 2004
67. Sato K, Nagayama H, Tadokoro K, Juji T, Takahashi TA: Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol 1999, 162:3865-3872
68. Livingston PO, Ritter G, Srivastava P, Padavan M, Calves MJ, Oettgen HF, Old LJ: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989, 49:7045-7050
69. Portoukalian J, Zwingelstein G, Dore JF, Bourgoin JJ: Studies of a ganglioside fraction extracted from human malignant melanoma. Biochimie 1976, 58:1285-1287
70. Geertsen R, Hofbauer G, Kamarashev J, Yue FY, Dummer R: Immune escape mechanisms in malignant melanoma. Int J Mol Med 1999, 3:49-57